1h Free Analyst Time
The fabry disease drugs market is forecasted to grow by USD 859.06 mn during 2023-2028, accelerating at a CAGR of 7.43% during the forecast period. The report on the fabry disease drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising incidence of rare diseases, availability of incentives for development of orphan drugs, and growing focus on research and development and FDA approval of fabry disease drugs.
The fabry disease drugs market is segmented as below:
By Distribution Channel
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
By Route Of Administration
- Intravenous route
- Oral route
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the fabry disease drugs market covers the following areas:
- Fabry disease drugs market sizing
- Fabry disease drugs market forecast
- Fabry disease drugs market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Distribution Channel
7 Market Segmentation by Route of Administration
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the global fabry disease drugs market: 4D Molecular Therapeutics Inc., Amicus Therapeutics Inc., CHIESI Farmaceutici SpA, Freeline Therapeutics Holdings plc, Idorsia Pharmaceuticals Ltd., Sangamo Therapeutics Inc., Sanofi SA, and Takeda Pharmaceutical Co. Ltd..Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is focus on strategic alliances and partnerships.'
According to the report, one of the major drivers for this market is the rising incidence of rare diseases.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 4D Molecular Therapeutics Inc.
- Amicus Therapeutics Inc.
- CHIESI Farmaceutici SpA
- Freeline Therapeutics Holdings plc
- Idorsia Pharmaceuticals Ltd.
- Sangamo Therapeutics Inc.
- Sanofi SA
- Takeda Pharmaceutical Co. Ltd.
